8-K: Moderna Reports Q2 2024 Results, Updates Financial Outlook Amidst Vaccine Approvals and Pipeline Progress

Moderna announced its second quarter 2024 financial results, including $241 million in revenue and a net loss of $1.3 billion, while also updating its 2024 financial framework and highlighting key pipeline advancements.

Summary

• Moderna reported second quarter 2024 revenue of $241 million, a decrease from $344 million in the same period last year, primarily due to lower COVID-19 vaccine sales.
• Net product sales were $184 million, down 37% year-over-year, reflecting the shift to a seasonal COVID-19 vaccine market.
• The company experienced a GAAP net loss of $1.3 billion, or $(3.33) per share, compared to a net loss of $1.4 billion, or $(3.62) per share, in the second quarter of 2023.
• Cost of sales decreased significantly to $115 million, down 84% from the previous year, due to lower sales volume and reduced manufacturing costs.
• Research and development expenses increased by 6% to $1.2 billion, driven by higher personnel costs.
• Selling, general, and administrative expenses decreased by 19% to $268 million due to cost discipline.
• Moderna revised its 2024 net product sales expectations to $3.0 to $3.5 billion, down from previous estimates, due to lower EU sales, potential revenue deferrals, and increased competition.
• The company's cash, cash equivalents, and investments totaled $10.8 billion as of June 30, 2024, down from $12.2 billion at the end of the previous quarter.
• Moderna received FDA approval for its RSV vaccine, mRESVIA, and began shipping in July, and also received a positive opinion from the EMA in June.
• Positive Phase 3 data was announced for both a combination vaccine against influenza and COVID-19 and a next-generation COVID-19 vaccine.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive developments such as the RSV vaccine approval and positive clinical trial data, the significant revenue decline, net loss, and reduced sales outlook temper the overall sentiment. The company is facing increased competition and market challenges.

Positives

• Moderna received FDA approval for its RSV vaccine, mRESVIA, and has begun shipping in the U.S.
• The company received a positive opinion from the EMA for its RSV vaccine, indicating potential for European market access.
• Positive Phase 3 data was reported for both a combination vaccine against influenza and COVID-19 and a next-generation COVID-19 vaccine, showing promising results.
• Cost of sales decreased significantly, by 84%, due to lower sales volume and reduced manufacturing costs.
• Selling, general, and administrative expenses decreased by 19%, reflecting cost discipline and efficiency improvements.
• Moderna's individualized neoantigen therapy (INT) in combination with KEYTRUDA showed sustained improvement in recurrence-free survival and distant metastasis-free survival in melanoma patients.
• Moderna's investigational therapeutic for MMA was selected by the U.S. FDA for the START pilot program, indicating accelerated development potential.
• David M. Rubenstein, Co-Founder and Co-Chairman of The Carlyle Group, will join Moderna's Board of Directors.

Negatives

• Moderna reported a net loss of $1.3 billion for the second quarter of 2024.
• Net product sales decreased by 37% compared to the same period in 2023.
• The company revised its 2024 net product sales expectations downwards to $3.0 to $3.5 billion.
• Moderna expects very low EU sales in 2024 due to ongoing negotiations.
• The company anticipates potential revenue deferrals for certain international sales into 2025.
• The company faces an increasingly competitive environment for respiratory vaccines in the U.S.
• Cash, cash equivalents, and investments decreased from $12.2 billion at the end of the previous quarter to $10.8 billion.

Risks

• The company faces an increasingly competitive environment for respiratory vaccines, which could impact sales.
• Lower than expected sales in the EU and potential revenue deferrals in international markets could negatively affect revenue.
• The company's financial performance is heavily reliant on the success of its respiratory vaccine portfolio.
• The company's research and development expenses remain high, impacting profitability.
• The company's cash position has decreased, primarily due to research and development expenses and operating activities.
• The company is subject to risks and uncertainties described in its SEC filings, which could cause actual results to differ materially from forward-looking statements.

Future Outlook

Moderna expects 2024 net product sales to be between $3.0 and $3.5 billion, with 40-50% of sales occurring in the third quarter and the remainder in the fourth quarter. The company anticipates full-year research and development expenses of approximately $4.5 billion, selling, general, and administrative expenses of approximately $1.3 billion, and capital expenditures of approximately $0.9 billion. Year-end cash and investments are projected to be approximately $9 billion.

Management Comments

• Stéphane Bancel, Chief Executive Officer of Moderna, stated that the company marked the approval of its second mRNA product and significantly lowered operating costs during the second quarter.
• He also mentioned that the company remains focused on execution for the 2024-25 COVID season and the launch of its RSV vaccine in the U.S.
• Bancel noted that with continued positive Phase 3 data across the respiratory portfolio, the company is using its mRNA platform to address significant unmet medical needs and advance public health.

Industry Context

Moderna's results reflect the evolving landscape of the vaccine market, with a shift towards seasonal demand for COVID-19 vaccines and increased competition in the respiratory vaccine space. The company's focus on expanding its pipeline beyond COVID-19, including RSV and influenza vaccines, is in line with broader industry trends towards addressing a wider range of infectious diseases. The positive Phase 3 data for combination vaccines and next-generation COVID-19 vaccines highlights the ongoing innovation in the mRNA vaccine space.

Comparison to Industry Standards

• Moderna's revenue decline in Q2 2024 is consistent with the expected shift in the COVID-19 vaccine market from pandemic-driven demand to seasonal demand, which is also being experienced by other vaccine manufacturers such as Pfizer and BioNTech.
• The company's cost of sales reduction is a positive sign, indicating improved efficiency in manufacturing and supply chain management, which is a key focus for all pharmaceutical companies.
• Moderna's R&D spending remains high, reflecting its commitment to developing new mRNA-based therapies, which is comparable to other biotech companies investing heavily in research and development.
• The approval of Moderna's RSV vaccine puts it in direct competition with other pharmaceutical companies like GSK and Pfizer, who also have RSV vaccines on the market.
• The positive Phase 3 data for Moderna's combination flu and COVID vaccine is a significant development, as it could potentially offer a more convenient and effective solution compared to separate vaccines, similar to efforts by other companies to develop combination vaccines.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the reduced revenue outlook and net loss.
• Employees may be impacted by the company's cost-cutting measures.
• Customers, including healthcare providers and pharmacies, will have access to Moderna's new RSV vaccine.
• Suppliers may be affected by changes in manufacturing and supply chain management.
• Creditors may be impacted by the company's financial performance.

Next Steps

• Moderna will continue to focus on the launch of its RSV vaccine in the U.S. and prepare for the upcoming COVID-19 vaccination season.
• The company will engage with regulators to file for approval of its seasonal flu vaccine and next-generation COVID-19 vaccine in 2024.
• Moderna will continue to advance its MMA program into a registrational study in 2024.
• The company will continue to engage with regulators on next steps for its combination vaccine against seasonal flu and COVID-19.
• Moderna will host an R&D Day on September 12.

Key Dates

Keywords

mRNA, Vaccine, COVID-19, RSV, Influenza, Financial Results, Net Sales, Clinical Trials, FDA Approval, Respiratory Vaccines